Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Depreciation & Amortization (CF) (2015 - 2025)

Alterity Therapeutics' quarterly Depreciation & Amortization (CF) came in at $1395.2 in Q4 2025, down 87.35% year-on-year from $11027.0 in Q4 2024, and down 87.35% quarter-over-quarter from $11027.0 in Q4 2024.

Alterity Therapeutics has reported Depreciation & Amortization (CF) for 11 years, with the latest figure at $1395.2 in Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 87.35% year-over-year to $1395.2; the trailing twelve-month figure through Dec 2025 stood at $12422.2 (down 45.93% YoY), and the FY2025 full-year result was $18128.7, down 22.17% from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 stood at $1395.2, down from $11027.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $12924.9 in Q4 2022, with the low at $1395.2 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $8421.1, with a median of $11027.0 recorded in 2024.
  • Year-over-year, Depreciation & Amortization (CF) surged 168.73% in 2022 and plunged 87.35% in 2025.
  • Tracing ATHE's Depreciation & Amortization (CF) over 5 years: stood at $4809.6 in 2021, then surged by 168.73% to $12924.9 in 2022, then retreated by 7.55% to $11948.9 in 2023, then decreased by 7.72% to $11027.0 in 2024, then sank by 87.35% to $1395.2 in 2025.
  • The last three Depreciation & Amortization (CF) figures came in at $1395.2 (Q4 2025), $11027.0 (Q4 2024), and $11948.9 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 2.35 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1,395.22
Dec 31, 2025 1,395.22
Dec 31, 2024 11,027.02
Dec 31, 2024 11,027.02
Dec 31, 2023 11,948.93
Dec 31, 2023 11,948.93
Dec 31, 2022 12,924.93
Dec 31, 2022 12,924.93
Dec 31, 2021 4,809.56
Dec 31, 2021 4,809.56
Jun 30, 2020 17,033.07
Jun 30, 2020 17,033.07
Dec 31, 2019 9,831.09
Dec 31, 2019 9,831.09
Jun 30, 2019 20,801.22
Jun 30, 2019 20,801.22
Dec 31, 2018 10,527.79
Dec 31, 2018 10,527.79
Jun 30, 2018 165.03
Jun 30, 2018 165.03
Dec 31, 2017 -7,171.28
Dec 31, 2017 -7,171.28
Jun 30, 2017 16,021.81
Jun 30, 2017 16,021.81
Dec 31, 2016 -7,888.67
Dec 31, 2016 -7,888.67
Jun 30, 2016 17,032.28
Jun 30, 2016 17,032.28
Dec 31, 2015 9,186.12
Dec 31, 2015 9,186.12